Valuation

PGENPrecigen Inc.

StockNasdaqUnited StatesHealth careEU retail investors: available

+5.8% today · +21.3% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 36% of the instruments we score

Stability: among the weakest; priced higher than most peers (P/E 69.5). No dividend.

Precigen Inc. (PGEN) valuation against sector peers: P/E 69.5 (sector median 30.9), P/B 20.2, EV/EBIT 51.9, free-cash-flow yield −4.4%, P/S 10.8.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricPGENSector medianvs median
P/E69.530.9 · n=159125% above
P/B20.24.0 · n=307412% above
P/S10.84.1 · n=299161% above
EV/EBIT51.925.6 · n=146103% above
Free-cash-flow yield−4.4%1.4% · n=288403% below
Dividend yield0.00%0.00% · n=362—
Return on equity38.8%−2.1% · n=308—
Return on invested capital23.5%0.6% · n=2823,551% above
Gross margin—63.3% · n=205—
Net debt / EBITDA1.271.27 · n=151near the median

Value factor: 34 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.233.0—1.5%0.6%6/10
JNJJohnson & Johnson42.28.3—3.0%1.9%8/10
ABBVAbbVie50.3—27.73.6%2.9%6/10
MRKMerck149.58.2—4.0%2.3%8/10
UNHUnitedHealth22.43.417.16.4%2.3%10/10
TMOThermo Fisher Scientific37.84.935.72.8%0.3%9/10
AMGNAmgen26.817.523.23.8%2.1%8/10
GILDGilead Sciences—16.1—6.6%1.9%5/10
ABTAbbott40.73.832.93.5%2.8%6/10
PFEPfizer41.31.9—7.1%7.4%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 04 Nov 2026